Alnylam Pharmaceuticals | ALNY - Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amgen USD 25.5B 547M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Incyte USD 1.44B 125.72M 2026-09
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.37B 4.1B 2026-03
PTC Therapeutics USD 776.08M 5.01M 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Takeda JPY 2.6T 161B 2026-09
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06
Xencor USD 81.86M 8.41M 2026-06